TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27611192
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol enriched margarine (3 g/d plant sterols)
Study: 27612924
Drug: Per-oral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral endoscopic tunneling for restoration of the esophagus (POETRE)
Study: 27612987
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan followed by autologous hematopoietic stem cell transplantation
Study: 27612987
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide) for 4-6 cycles
Study: 27612987
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood stem cells collected after high-dose cyclophosphamide plus G-CSF or G-CSF alone
Study: 27612987
Drug: Melphalan at
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan at 140 mg/m² as conditioning regimen
Study: 27613072
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) lot released between August 1 and September 15, 2013
Study: 27613072
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) lot shipped earlier or later than August 1 to September 15, 2013
Study: 27613072
Drug: LAIV (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAIV (trivalent or quadrivalent formulations)
Study: 27613189
Drug: L-DEP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DEP regimen (PEG-aspargase and modified DEP regimen)
Study: 27614912
Drug: [(14)C]prucalopride succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(14)C]prucalopride succinate 2 mg (~200 nCi)
Study: 27616553
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg once daily; 28-day cycle)
Study: 27617496
Drug: Interferon-based therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-based therapy
Study: 27618501
Drug: Once-daily degludec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily degludec
Study: 27618681
Drug: Objective criteria
Normalized name: .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SILICON DIOXIDE 4 g in 100 g DENTAL PASTE, DENTIFRICE [the naked object DeBlack PackToothpaste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective criteria for identifying patients with OHCA with no chance of survival (not witnessed by emergency medical services, nonshockable initial cardiac rhythm, no return of spontaneous circulation before a third 1-mg dose of epinephrine)
Study: 27619225
Drug: Topical travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical travoprost
Study: 27621400
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity
Study: 27621833
Drug: Low eosinophil
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low eosinophil counts (<0.05 compared with 0.15-0.25×10(9)/L)
Study: 27621833
Drug: Low lymphocyte
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lymphocyte counts (<1.45 vs 1.85-2.15×10(9)/L)
Study: 27622077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEDI9447 and anti-PD-1 antibodies
Study: 27623532
Drug: Task-oriented training
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented training with interactive computer games and objects of daily life
Study: 27624549
Drug: Decitabine at
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine at 20 mg/m²
Study: 27624571
Drug: Healthcare-associated infections,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare-associated infections, obstructive urinary tract disease, previous surgical history, and use of a cephalosporin antibiotic within 3 months
Study: 27624579
Drug: Hyperglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic clamp (225 and 400 mg/dl) followed by IV arginine bolus
Study: 27625358
Drug: HLA allele-matched
Normalized name: Human Factor XIII (A2) homodimer (allele F13A*1B), recombinant DNA origin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA allele-matched unrelated donor transplant with conditioning regimen including alemtuzumab, fludarabine, and melphalan; GVHD prophylaxis with calcineurin inhibitor, short-course methotrexate, and methylprednisolone.
Study: 27627050
Drug: Nintedanib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (150 mg for mild impairment, 100 mg for moderate impairment, escalating to 200 mg)
Study: 27630572
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of five or more medicinal molecules
Study: 27632289
Drug: HER2-targeted therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HER2-targeted therapy (trastuzumab/pertuzumab)
Study: 27632680
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor-modified T cell therapy
Study: 27632680
Drug: Tocilizumab (interleukin-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (interleukin-6 receptor antibody)
Study: 27633122
Drug: Sandoz biosimilar
Normalized name: CLOZAPINE (SANDOZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoz biosimilar filgrastim, administered twice daily
Study: 27634203
Drug: Momelotinib 200
Normalized name: momelotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib 200 mg twice daily
Study: 27634566
Drug: Pazopanib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib at 800 mg oral daily until disease progression
Study: 27635072
Drug: Extensive cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensive cardiac workup including ECG, signal averaged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testing with epinephrine or procainamide
Study: 27635623
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) delivered in 5 fractions to a dose of 25 to 40 Gy
Study: 27636400
Drug: FLARE-RA self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLARE-RA self-administered questionnaire
Study: 27637014
Drug: Anti-mullerian hormone
Normalized name: Anti-Mullerian hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-mullerian hormone (AMH)
Study: 27637428
Drug: Romidepsin at
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin at 14 mg/m²
Study: 27637985
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg orally once daily until progressive disease or unacceptable toxicity
Study: 27642132
Drug: MenACWY-D (0.5-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-D (0.5-mL booster dose)
Study: 27642534
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (a combination of aerobic, resistance, and flexibility exercises, average of 2.5 hours a week)
Study: 27642538
Drug: Metreleptin (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.02 mg/kg BID at Week 1, 0.04 mg/kg BID at Week 2, maximum 0.08 mg/kg BID thereafter)
Study: 27643485
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg, two infusions
Study: 27644734
Drug: Anti-tissue transglutaminase
Normalized name: Anti-tissue transglutaminase IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tissue transglutaminase (anti-tTG) IgA antibodies
Study: 27644734
Drug: Anti-deamidated gliadin
Normalized name: Anti-deamidated gliadin peptide IgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-deamidated gliadin peptide (anti-DGP) IgA antibodies
Study: 27646946
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks
Study: 27647168
Drug: NOACs (Novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs (Novel Oral Anticoagulants)
Study: 27647168
Drug: VKA±AP (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA±AP (Vitamin K Antagonists plus Antiplatelet) or AP (Antiplatelet) alone
Study: 27647864
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg, days 1-21/28 days) + continuous cyclophosphamide (50 mg/d) + prednisone (20 mg/d)
Study: 27648290
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral nutritional supplement (ONS)
Study: 27648294
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² on day 1 and capecitabine 900 mg/m² two times per day from day 1 to day 14 every 3 weeks (2 cycles)
Study: 27649927
Drug: Perifosine 50-75
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine 50-75 mg
Study: 27650822
Drug: Early β
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early β blockers (≤48 hours of admission)
Study: 27650822
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers at discharge
Study: 27650822
Drug: Persistence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistence of β blockers at one year
Study: 27651909
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) containing fluticasone propionate
Study: 27653085
Drug: MedGem (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedGem (MG) vs VMax
Study: 27653529
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b therapy
Study: 27653565
Drug: KAF156 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 multiple doses (400 mg once daily for 3 days)
Study: 27653565
Drug: KAF156 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 single dose (800 mg)
Study: 27653771
Drug: Single challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines)
Study: 27654603
Drug: Second anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second anti-TNF drug
Study: 27654882
Drug: Niacin 500
Normalized name: niacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 500 mg q1h for 4 doses
Study: 27654882
Drug: Niacin 500
Normalized name: niacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 500 mg q2h for 3 doses
Study: 27654882
Drug: Niacin 250
Normalized name: niacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 250 mg q2h for 3 doses
Study: 27654985
Drug: Tenapanor hydrochloride
Normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenapanor hydrochloride (15 mg twice daily) with sevelamer carbonate (800 mg 3 times daily)
Study: 27654985
Drug: Tenapanor hydrochloride
Normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenapanor hydrochloride (15 mg twice daily) without sevelamer carbonate
Study: 27656788
Drug: Ketamine (0.5mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5mg/kg, administered over 100min) during acute-phase treatment (up to 6 thrice-weekly infusions)
Study: 27656788
Drug: Continuation-phase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase treatment with 4 weekly ketamine infusions
Study: 27656788
Drug: Post-continuation phase
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-continuation phase follow-up (4 weeks, no further ketamine infusions)
Study: 27656788
Drug: Acute-phase and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute-phase and continuation-phase treatment
Study: 27658471
Drug: Fecal Microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal Microbiota Transplant (FMT) via duodenal route (44.4%), colonic (41.1%), capsule (9.8%), gastric (3.0%)
Study: 27658581
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/kg
Study: 27658740
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg daily for 12 weeks
Study: 27658863
Drug: Vacc-4x (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacc-4x (12 mg/mL) and rhuGM-CSF (0.6 mg/mL) administered intradermally over 12 weeks followed by romidepsin (5 mg/m2) intravenously once a week for 3 weeks.
Study: 27658863
Drug: Romidepsin treatment
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin treatment (5 mg/m2) administered intravenously once a week for 3 weeks.
Study: 27658863
Drug: Vacc-4x and
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacc-4x and rhuGM-CSF followed by romidepsin treatment.
Study: 27658864
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg long-acting rilpivirine
Study: 27658864
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg long-acting rilpivirine
Study: 27658870
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) taken as one tablet per day for a median of 72 weeks
Study: 27658980
Drug: Acute leukoencephalopathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute leukoencephalopathy during chemotherapy treatment
Study: 27659464
Drug: First NGAL
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First NGAL <150 ng/ml
Study: 27660663
Drug: Twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily insulin lispro low mixture (LM25)
Study: 27660663
Drug: Once-daily basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL)
Study: 27664062
Drug: Gla-300 (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gla-300 (insulin glargine 300 U/mL)
Study: 27664804
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of glycine and kynurenine alone or in combination
Study: 27666002
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with ticagrelor (at least 1.5h before PCI)
Study: 27666002
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (ticagrelor administered immediately before PCI)
Study: 27668024
Drug: Effervescent NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effervescent NAC tablets
Study: 27668024
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution NAC
Study: 27669017
Drug: High-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inactivated influenza vaccine (IIV-HD)
Study: 27669017
Drug: Standard-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose inactivated influenza vaccine (SD)
Study: 27669747
Drug: FPG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG target ≤5.6 mmol/L
Study: 27669747
Drug: FPG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG target ≤6.1 mmol/L
Study: 27669747
Drug: FPG target
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG target ≤7.0 mmol/L
Study: 27670519
Drug: Behavioural Couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Couples Therapy (BCT) involving the gambler and the CSO
Study: 27670519
Drug: Cognitive-Behavioural Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioural Therapy (CBT) involving the gambler alone
Study: 27671037
Drug: Value-based formulary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Value-based formulary which eliminates copayment for high-value preventive medications
Study: 27671037
Drug: Comprehensive self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive self-management support program promoting health behavior change and medication adherence
Study: 27671037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of value-based formulary and self-management support program
Study: 27672408
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate 0.05% gel after cryosurgery
Study: 27676257
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate PrEP administered through daily directly observed therapy (DOT) for ten consecutive days.
Study: 27677166
Drug: Lower serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower serum albumin (per 0.5 g/dl decrease)
Study: 27677442
Drug: Lower consumption
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower consumption frequencies of butter, cream cake, French fries, or high-percentage alcoholic beverages.
Study: 27678432
Drug: Atorvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (5 mg or 10 mg, increased to up to 80 mg based on LDL-C levels)
Study: 27678541
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant alkaline phosphatase (recAP) 0.4 mg/kg
Study: 27678541
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant alkaline phosphatase (recAP) 0.8 mg/kg
Study: 27678541
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant alkaline phosphatase (recAP) 1.6 mg/kg
Study: 27678541
Drug: Most efficacious
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most efficacious dose of recAP (to be determined in Part 2)
Study: 27678545
Drug: Whole soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole soy replacement diet (4 servings of whole soy foods containing 25g soy protein daily, replacing red or processed meat and high fat dairy products)
Study: 27680873
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral glucocorticoid treatment
Study: 27680875
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) - leuprolide 3.75-mg administered for 4 weeks
Study: 27681711
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three strategies
Study: 27681866
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg daily with sorafenib 400 mg twice daily
Study: 27683610
Drug: Control (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (other FDA-approved PAH therapies)
Study: 27686833
Drug: JE-CV vaccine
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV vaccine in MBDV-primed 2-5-year-olds (n=78)
Study: 27686833
Drug: JE-CV vaccine
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV vaccine in JE-vaccine-naïve toddlers
Study: 27687127
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during low-fat diet phase
Study: 27687127
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during habitual diet phase
Study: 27690095
Drug: Conventional vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vitamin D treatment (0.25 mcg alfacalcidol plus placebo 3×/week)
Study: 27690095
Drug: Intensive vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vitamin D treatment (0.25 mcg alfacalcidol 3×/week plus 50,000 IU ergocalciferol 1×/week)
Study: 27692306
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Study: 27692306
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral factor Xa inhibitors
Study: 27692920
Drug: Intra-prostatic boost
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-prostatic boost dose of 68 Gy
Study: 27693556
Drug: selinexor and
Approvals — FDA: no, EMA: no, PMDA: no
Description: selinexor and related SINE compounds